Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | CPT2 | P23786 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15457453 | 0.87 | MAPT (0.37) | FFAR1CPT2TDP1ALDH1A1 | |
| SCHEMBL25885737 | 0.84 | MAPT (0.41) | FFAR1CPT2TDP1ALDH1A1 | |
| SCHEMBL12384259 | 0.84 | FFAR1 (0.32) | FFAR1CPT2TDP1 | |
| SCHEMBL15183708 | 0.82 | ALDH1A1 (0.31) | FFAR1CPT2TDP1ALDH1A1 | |
| SCHEMBL12856152 | 0.81 | FFAR1 (0.33) | FFAR1CPT2TDP1 | |
| SCHEMBL2527740 | 0.80 | CAMK2A (0.42) | FFAR1CPT2TDP1PLA2G4A | |
| SCHEMBL2527737 | 0.80 | PLA2G4A (0.31) | FFAR1CPT2TDP1PLA2G4A | |
| SCHEMBL12425764 | 0.80 | CES1 (0.48) | TDP1PLA2G4AALDH1A1 | |
| SCHEMBL2739382 | 0.80 | TDP1 (0.43) | FFAR1CPT2TDP1ALDH1A1 | |
| SCHEMBL15457429 | 0.79 | MAPT (0.41) | FFAR1CPT2TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364277-A1 | E-SELECTIN TARGETING AGENTS | GLYCOMIMETICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230271998-A1 | SOLID SUPPORT FOR SYNTHESIZING NUCLEIC ACID SEQUENCES AND METHODS FOR MAKING AND USING | UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230167149-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | GLYCOMIMETICS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167150-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | GLYCOMIMETICS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20180161446-A1 | ANTIBODY DRUG CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USES THEREOF | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2018-06-14 | — | — | US | disclosed |
| US-20170368189-A1 | CNP PRODRUGS | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2017-12-28 | — | — | US | disclosed |
| US-20160214973-A1 | STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME | UTI LIMITED PARTNERSHIP (CA) | 2016-07-28 | — | — | US | disclosed |
| US-9320803-B2 | Bisphosphonate-prodrugs | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | 2016-04-26 | — | — | US | disclosed |
| US-8778914-B2 | Bisphosphonate-prodrugs | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | 2014-07-15 | — | — | US | disclosed |
| US-20140051623-A1 | Bisphosphonate-Prodrugs | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | 2014-02-20 | — | — | US | disclosed |
| US-20130231260-A1 | POLYMER SCAFFOLDS FOR ASSAY APPLICATIONS | NVS Technologies, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20120165296-A1 | BISPHOSPHONATE-PRODRUGS | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | 2012-06-28 | — | — | US | disclosed |
| EP-0531715-B1 | Process for producing alcohols and ketones | SUMITOMO CHEMICAL CO (JP) | 1997-11-05 | — | — | EP | disclosed |
| US-5426237-A | Oxidation of straight, branched or cyclic alkanes and benzene derivatives in presence of transition metal catalyst and aldehyde | SUMITOMO CHEMICAL CO., LTD. (JP) | 1995-06-20 | — | — | US | disclosed |
| EP-0531715-A1 | Process for producing alcohols and ketones | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167150-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | SIGLEC7, SIGLEC9, CD47 | FFAR1 1265/4885CPT2 4477/4885TDP1 2678/4885 |
| US-20140051623-A1 | Bisphosphonate-Prodrugs | BPGM, PIK3CA, PPA1 | FFAR1 1010/4885CPT2 3351/4885TDP1 2494/4885 |
| US-20120165296-A1 | BISPHOSPHONATE-PRODRUGS | BPGM, PIK3CA, PPA1 | FFAR1 1010/4885CPT2 3351/4885TDP1 2494/4885 |
| US-20160214973-A1 | STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME | ORAI1, RYR2, CASR | FFAR1 318/4885CPT2 840/4885TDP1 3331/4885 |
| US-20230167149-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | SIGLEC7, SIGLEC9, ASGR1 | FFAR1 1318/4885CPT2 4307/4885TDP1 2714/4885 |
| US-20230364277-A1 | E-SELECTIN TARGETING AGENTS | SELE, SELPLG, SELP | FFAR1 3278/4885CPT2 4035/4885TDP1 3975/4885 |
| US-20180161446-A1 | ANTIBODY DRUG CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USES THEREOF | FCGR3B, SI, INCENP | FFAR1 4444/4885CPT2 2509/4885TDP1 4315/4885 |
| US-20230271998-A1 | SOLID SUPPORT FOR SYNTHESIZING NUCLEIC ACID SEQUENCES AND METHODS FOR MAKING AND USING | RNGTT, NSUN2, POLN | FFAR1 3603/4885CPT2 4827/4885TDP1 453/4885 |
| US-20170368189-A1 | CNP PRODRUGS | NPPA, NPR1, NPR3 | FFAR1 1199/4885CPT2 3058/4885TDP1 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.